ORTX - Orchard Therapeutics GAAP EPS of -$0.07 beats by $0.55 revenue of $7.3M beats by $0.81M
2023-08-03 08:44:39 ET
- Orchard Therapeutics press release ( NASDAQ: ORTX ): Q2 GAAP EPS of -$0.07 beats by $0.55 .
- Revenue of $7.3M (+67.0% Y/Y) beats by $0.81M .
-
The company expects its cash used to fund operations in 2023 to decline as compared to 2022 due to an anticipated increase in revenue from Libmeldy product sales and ongoing management of operating expenses.
-
As of June 30, 2023, the company reported cash, cash equivalents and investments of approximately $155.0 million, with $27.9 million of debt outstanding, compared to $148.0 million and $32.4 million of debt outstanding as of December 31, 2022.
-
Orchard Therapeutics expects that its existing cash, cash equivalents and investments will fund its anticipated operating, debt service and capital expenditure requirements to mid-2025.
For further details see:
Orchard Therapeutics GAAP EPS of -$0.07 beats by $0.55, revenue of $7.3M beats by $0.81M